Responses
Poster Presentations
Rheumatoid arthritis - anti-TNF therapy
FRI0162 Comparable Safety and Immunogenicity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product in Patients with Rheumatoid Arthritis: Results of Phase III Transition Study
Compose a Response to This Article
Other responses
No responses have been published for this article.